Last reviewed · How we verify

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

NCT02133664 Phase 1/Phase 2 COMPLETED Results posted

The primary aim is to collect data to determine the correct effect size on the primary outcome to aid in the design of a larger study: The primary outcome is to determine if lipoic acid and omega-3 fatty acids can improve cognitive function in people with multiple sclerosis that have cognitive dysfunction.

Details

Lead sponsorOregon Health and Science University
PhasePhase 1/Phase 2
StatusCOMPLETED
Enrolment54
Start date2014-06
Completion2016-05

Conditions

Interventions

Primary outcomes

Countries

United States